Inmune Bio (INMB) Net Cash Flow Growth (3y) (2021 - 2026)
Inmune Bio (INMB) Net Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -35.85% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 106.37% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 67.39% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -70.95% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 52.78% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.55% |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | -0.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.24% |
| Mar 31, 2026 | -43.94% |
| Dec 31, 2025 | 18.56% |
| Sep 30, 2025 | -18.44% |
| Jun 30, 2025 | 72.47% |
| Mar 31, 2025 | 42.46% |
| Dec 31, 2024 | -10.32% |
| Sep 30, 2024 | -60.35% |
| Jun 30, 2024 | -17.92% |
| Mar 31, 2024 | -34.38% |
| Dec 31, 2023 | -35.27% |
| Sep 30, 2023 | -30.42% |
| Jun 30, 2023 | -40.11% |
| Mar 31, 2023 | -3.01% |
| Dec 31, 2022 | -135.98% |
| Sep 30, 2022 | -20.06% |
| Jun 30, 2022 | -50.73% |
| Mar 31, 2022 | -50.19% |
| Dec 31, 2021 | -176.55% |
| Sep 30, 2021 | 367.32% |